Drug Delivery Outsourcing In A World Of Pharma’s Shifting Sands
Executive Summary
The contract drug delivery industry is facing disruptive influences from an evolving client base, the increase in biologics manufacturing and specialty pharma needs. In Vivo speaks to Catalent’s vice president of strategy, Cornell Stamoran, about the evolution of the industry and the continuous search for efficiency.
You may also be interested in...
A New Generation Invents Pharma’s Mirrored Future
Young businesses are getting set to disrupt every inch of the healthcare space with digital twin technology. Outlook spoke to two startups on the brink of a data dawn.
MeMed’s Mission: Pressing Its Fingerprint Against AMR
Approved in Europe and just given the US green light, MeMed is making waves in the fight against antimicrobial resistance using advanced "host response" technology. Its CEO talks to In Vivo about strategy, commercialization and earning the right to fantasize.
Raising The Stakes: Immunocore’s Next Play
Two years into her tenancy as CEO, Bahija Jallal is on the cusp of taking UK biotech Immunocore from a research and development organization to a company with a burgeoning pipeline and a marketed therapy. She talks to In Vivo about validating the platform, an IPO and creating a commercial footprint.